COLL - NASDAQ
Collegium Pharmaceutical, Inc.
$32.20
+5.6%Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
At a Glance
Live SnapshotCollegium Pharmaceutical, Inc. Management Team
Mr. Vikram Karnani
Chief Executive Officer, President, Executive Vice President & Director
Compensation
$728,431
Mr. Dean J. Patras
Chief People Officer
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.
Co-Founder & Chairman
Compensation
$304,348
Mr. Scott Dreyer
Executive Vice President & Chief Commercial Officer
Compensation
$935,915
Ms. Colleen Tupper
Executive Vice President & Chief Financial Officer
Compensation
$1,037,638
Dr. Thomas B. Smith FAAFP, M.D.
Executive Vice President & Chief Medical Officer
Compensation
$867,278
Ms. Jane Gonnerman
Executive Vice President of Strategy & Corporate Development
Mr. David Dieter
Executive Vice President, General Counsel & Corporate Secretary
Mr. Scott Sudduth
Head of Technical Operations
Collegium Pharmaceutical, Inc. Insider Positioning
During the last 12 months, insiders have sold $6.36M worth of COLL shares, with no buying activity reported.
3 Months
0
0.00
31.3K
1.12M
-1.1M
-$1.12M
3-6 Months
0
0.00
57.5K
2.41M
-2.4M
-$2.41M
6-9 Months
0
0.00
63.6K
2.83M
-2.8M
-$2.83M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Dreyer Scott
Officer: Evp & Chief Commercial Officer
$2.41M
Fallon John A.
Director
$1.65M
Tupper Colleen
Officer: Evp & Chief Financial Officer
$1.02M
Dieter David
Officer: Evp & General Counsel
$488K
Bohlin Garen G
Director
$323K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $6.36M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
COLL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | May 14, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 28, 2025 | May 15, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 05, 2024 | May 16, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 11, 2023 | April 11, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 06, 2022 | May 19, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 07, 2021 | May 20, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 09, 2020 | May 20, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 15, 2019 | April 25, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 13, 2018 | May 24, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 13, 2017 | May 24, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.